EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease

Andrea Pilotto, Nicholas J Ashton, Alessandro Lupini, Beatrice Battaglio, Cinzia Zatti, Chiara Trasciatti, Stefano Gipponi, Elisabetta Cottini, Ilaria Grossi, Alessandro Salvi, Giuseppina de Petro, Marina Pizzi und 4 weitere

Journal of Neurology · 2024-12 · 271 (12) · 7537-7546

DOI: 10.1007/s00415-024-12669-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurology, online erschienen am 09.09.2024. Verfasst von Andrea Pilotto und 15 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, P.Zzale Spedali Civili, 1, 25123, Brescia, Italy. Andrea.pil…. Hauptthemen laut MEDLINE: Parkinson Disease, tau Proteins, Neurofilament Proteins, Glial Fibrillary Acidic Protein. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Wealth research grants 2016 of the University of Brescia, AD Strategic Fund and the Alzheimer's Association, PNRR-Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The prognostic role of plasma neurofilament light chain (NfL), phospho-tau, beta-amyloid, and GFAP is still debated in Parkinson’s disease (PD).

Methods

Plasma p-tau181, p-tau231, Aβ1-40, Aβ1-42, GFAP, and NfL were measured by SIMOA in 136 PD with 2.9 + 1.7 years of follow-up and 76 controls. Differences in plasma levels between controls and PD and their correlation with clinical severity and progression rates were evaluated using linear regression analyses.

Results

Patients exhibited similar distribution of plasma biomarkers but higher P-tau181, P-tau231 and lower Aβ1-42 compared with controls. NfL and GFAP correlated with baseline motor and non-motor severity measures. At follow-up, NfL emerged as the best predictor of progression with marginal effect of GFAP and p-tau181 adjusting for age, sex, disease duration, and baseline motor severity.

Conclusion

The present findings confirmed plasma NfL as best predictor of progression in PD, with a marginal role of p-tau181 and GFAP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson Diseasetau ProteinsNeurofilament ProteinsGlial Fibrillary Acidic ProteinBiomarkersAmyloid beta-PeptidesDisease ProgressionHumansFemaleMaleMiddle AgedAgedPrognosisPeptide FragmentsFollow-Up StudiesPhosphorylationSeverity of Illness Index

Stichwörter der Autor:innen

GFAPNeurofilament light chainParkinson’s diseasePhosphorylated tauPlasma biomarkersProgression

Substanzen

tau ProteinsNeurofilament Proteinsneurofilament protein LGlial Fibrillary Acidic ProteinBiomarkersAmyloid beta-PeptidesGFAP protein, humanamyloid beta-protein (1-42)Peptide FragmentsMAPT protein, human

Autor:innen und Institutionen

  • Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, P.Zzale Spedali Civili, 1, 25123, Brescia, Italy. Andrea.pilotto@unibs.it.
  • Department of Continuity of Care and Frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy. Andrea.pilotto@unibs.it.
  • Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy. Andrea.pilotto@unibs.it.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Swe…
  • King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.

Förderung

  • Health and Wealth research grants 2016 of the University of Brescia
  • AD Strategic Fund and the Alzheimer's Association
  • PNRR-Health
  • European Union Joint Program for Neurodegenerative Disorders
  • Swedish Research Council
  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • EU Joint Programme - Neurodegenerative Disease Research
  • ALF-agreement

Zitieren

APA

Pilotto, A., Ashton, N. J., Lupini, A., Battaglio, B., Zatti, C., Trasciatti, C., Gipponi, S., Cottini, E., Grossi, I., Salvi, A., de Petro, G., Pizzi, M., Canale, A., Blennow, K., Zetterberg, H., & Padovani, A. (2024). Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease. Journal of Neurology, 271(12), 7537-7546. https://doi.org/10.1007/s00415-024-12669-7

Vancouver

Pilotto A, Ashton NJ, Lupini A, Battaglio B, Zatti C, Trasciatti C, et al. Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease. Journal of Neurology. 2024;271(12):7537-7546. doi:10.1007/s00415-024-12669-7

BibTeX
@article{Pilotto2024,
  author = {Pilotto, Andrea and Ashton, Nicholas J and Lupini, Alessandro and Battaglio, Beatrice and Zatti, Cinzia and Trasciatti, Chiara and Gipponi, Stefano and Cottini, Elisabetta and Grossi, Ilaria and Salvi, Alessandro and de Petro, Giuseppina and Pizzi, Marina and Canale, Antonio and Blennow, Kaj and Zetterberg, Henrik and Padovani, Alessandro},
  title = {Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease},
  journal = {Journal of Neurology},
  year = {2024},
  volume = {271},
  number = {12},
  pages = {7537--7546},
  doi = {10.1007/s00415-024-12669-7}
}
Kostenlos starten →